Login to Your Account



Portola, BMS, Pfizer Team Up to Test Their Drugs' Antidote

By Randy Osborne
Staff Writer

Monday, November 5, 2012
Not every day do you see a company, in the course of developing its drug, sign a deal with two other firms that are working on a therapy in the same class. Even more unusual: The deal is designed to help come up with a reversing agent for both compounds, and others.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription